Integrated Quantitative Investments LLC Buys New Position in AngioDynamics, Inc. $ANGO

Integrated Quantitative Investments LLC bought a new position in shares of AngioDynamics, Inc. (NASDAQ:ANGO) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,302 shares of the medical instruments supplier’s stock, valued at approximately $241,000. Integrated Quantitative Investments LLC owned 0.06% of AngioDynamics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Cerity Partners LLC boosted its position in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock valued at $121,000 after purchasing an additional 2,333 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in AngioDynamics during the second quarter valued at approximately $139,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in AngioDynamics during the first quarter valued at approximately $139,000. Fox Run Management L.L.C. bought a new stake in AngioDynamics during the first quarter worth approximately $145,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in AngioDynamics in the first quarter worth approximately $213,000. 89.43% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ANGO has been the subject of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group boosted their target price on AngioDynamics from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a report on Saturday, October 4th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, AngioDynamics presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $11.91 on Tuesday. The firm’s 50 day moving average price is $11.49 and its two-hundred day moving average price is $10.26. AngioDynamics, Inc. has a twelve month low of $6.63 and a twelve month high of $13.50. The stock has a market cap of $490.69 million, a price-to-earnings ratio of -15.27 and a beta of 0.74.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.The company had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, research analysts forecast that AngioDynamics, Inc. will post -0.37 EPS for the current fiscal year.

Insider Transactions at AngioDynamics

In related news, CEO James C. Clemmer purchased 10,000 shares of AngioDynamics stock in a transaction dated Thursday, October 9th. The stock was acquired at an average cost of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Lawrence T. Weiss purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The shares were bought at an average price of $11.81 per share, with a total value of $118,100.00. Following the completion of the acquisition, the senior vice president owned 93,597 shares of the company’s stock, valued at $1,105,380.57. This trade represents a 11.96% increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 20,890 shares of company stock valued at $239,532 over the last 90 days. Corporate insiders own 6.00% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.